Antimicrobial Agents and Resistance


The development and spread of drug-unaffected pathogens that have developed new battle mechanisms, leading to antimicrobial resistance, carry on to  portend our ability to treat common infections. Especially alarming is the rapid global spread of multi- and pan-resistant bacteria (also known as “superbugs”) that cause infections that are not treatable with existing antimicrobial medicines such as antibiotics.

The clinical pipeline of new antimicrobials is dry. In 2019 WHO identified 32 antibiotics in clinical development that address the WHO list of priority pathogens, of which only six were classified as innovative. Furthermore, a lack of access to quality antimicrobials remains a major issue. Antibiotic shortages are affecting countries of all levels of development and especially in health- care systems.



 


    Antimicrobial Agents and Resistance Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in